Total Ischemic Event Reduction With Rivaroxaban Afte Revascularization in the VOYAGER PAD Trial

Journal of the American College of Cardiology

78, 317-326

DOI: 10.1016/j.jacc.2021.05.003

Citation Report

#	Article	IF	Citations
1	Wider Lens, Sharper Focus. Journal of the American College of Cardiology, 2021, 78, 327-329.	12.0	0
2	Improving Medical Adherence and Antithrombotic Management for Patients With Chronic Limb Threatening Ischaemia in Singapore. Annals of the Academy of Medicine, Singapore, 2021, 50, 795-797.	1.1	5
3	Aspects of Antithrombotic and Anticoagulant Therapies in Patients Undergoing Endovascular Procedures for Lower Extremity Arterial Disease. Orvosi Hetilap, 2022, 163, 98-108.	0.9	1
4	Pharmacodynamic Profiles of Dual-Pathway Inhibition With or Without Clopidogrel Versus Dual Antiplatelet Therapy in Patients With Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	4.6	21
5	Editor-in-Chief's Top Picks From 2021. Journal of the American College of Cardiology, 2022, 79, 695-753.	12.0	1
6	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
7	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, e025504.	5.8	14
8	Endovascular Bypass as a Strategy for Long Femoropopliteal Lesions. Journal of Cardiovascular Surgery, 2022, 63, 562-574.	0.8	4
9	Clinical Outcomes After Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients With Anticoagulant Versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study. Journal of Cardiovascular Development and Disease, 2022, 9, 207.	2.9	1
10	Aortic Calcification Index Predicts Mortality and Cardiovascular Events in Operatively Treated Patients With Peripheral Artery Disease: A Prospective PURE ASO Cohort Follow-Up Study. Journal of Vascular Surgery, 2022, 76, 1657-1666.e2.	3.4	9
11	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
12	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. Seminars in Interventional Radiology, 2022, 39, 364-372.	1.1	2
13	Evolution in Trends of Primary Lower-Extremity Amputations Associated With Diabetes or Peripheral Artery Disease From 2006 to 2019. Canadian Journal of Cardiology, 2023, 39, 321-330.	3.8	15
14	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions With the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. International Journal of Molecular Sciences, 2022, 23, 14914.	5.9	35
15	Risk of Bleeding After Percutaneous Coronary Intervention and Its Impact on Further Adverse Events in Clinical Trial Participants With Comorbid Peripheral Arterial Disease. International Journal of Cardiology, 2023, 374, 27-32.	3.2	8
16	Tradeoffs in Approach to PAD Revascularization: Shared Decision Making in the Spotlight. Journal of the American College of Cardiology, 2023, 81, 371-373.	12.0	1
17	A Multicenter, Randomized, Open-Labelled, Non-Inferiority Trial of Sustained-Release Sarpogrelate Versus Clopidogrel After Femoropopliteal Artery Intervention. Scientific Reports, 2023, 13, 1-10.	5.2	5
18	Evidenzbasierte Gefäßchirurgie. Evidenzbasierte Chirurgie, 2022, .	0.0	2

#	Article	IF	Citations
19	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
20	Peripheral Arterial Disease and the Pharmacist's Role in Management. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	0
21	Interventionelle Therapie der peripheren arteriellen Verschlusskrankheit. Deutsche Medizinische Wochenschrift, 2023, 148, 1301-1306.	0.3	1
22	Editor's Choice – European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication☆. European Journal of Vascular and Endovascular Surgery, 2024, 67, 9-96.	3.2	532
23	Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2024, 17, 1-13.	5.0	21
24	Evidence-Based Therapy in Vascular Surgery. , 2023, .		0
25	Gefäßchirurgie. , 2024, .		0
26	Pharmacotherapy and Revascularization Strategies of Peripheral Artery Disease. Current Problems in Cardiology, 2024, 49, 102430.	4.1	10
27	The Paradox of Direct-Acting Anticoagulants in Peripheral Arterial Disease in Spain. Angiologia, 2024, .	0.1	0
28	Precision Monitoring of Antithrombotic Therapy in Cardiovascular Disease. Cardiovascular Innovations and Applications, 2024, 9, 961.	1.3	4
29	Chronic Limb-Threatening Ischemia With No Revascularization Option: Result From a Multidisciplinary Care Model. European Journal of Internal Medicine, 2024, 0, 137-138.	4.2	1
30	Dual-Pathway Inhibition in Patients With Chronic Limb-Threatening Ischemia Requiring Reintervention for Infrapopliteal Occlusions. Heart and Vessels, 2024, 39, 771-777.	1.8	1
31	Medical Therapy for Peripheral Artery Disease. Current Cardiology Reports, 2024, 26, 651-659.	4.5	13
32	2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2024, 83, 2497-2604.	12.0	309
33	2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024, 149, e1313-e1410.	24.6	781
34	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
35	Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. Journal of the American College of Cardiology, 2024, 84, 801-811.	12.0	12
36	Clinical Outcomes of Acute Limb Ischaemia Caused by Femoropopliteal Stent Thrombosis. EuroIntervention, 2024, 20, e1163-e1172.	4.9	2

#	Article	IF	Citations
37	Design and Baseline Characteristics of the STRIDE Trial: Evaluating Semaglutide in People With Symptomatic Peripheral Artery Disease and Type 2 Diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2025, 10, 728-737.	5.0	24
38	Improving Peripheral Artery Disease Screening and Treatment: A Screening, Diagnosis, and Treatment Tool for Use Across Multiple Care Settings. Journal of Osteopathic Medicine, 2025, 125, 163-171.	1.5	1
39	Clinical Outcomes Following Low-Dose Second-Generation "Ranger" Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease. Journal of Endovascular Therapy, 2026, 33, 1270-1277.	2.1	8
40	Implementing the 2024 ACC/AHA Multisocietal PAD Guidelines Into Clinical Practice: Key Changes From the 2016 Guidelines. Vascular Medicine, 2025, 30, 110-113.	2.3	0
41	One-Year Results of Endovascular Treatment of Long Femoropopliteal Lesions With Viabahn® Stent Graft. Journal of Endovascular Therapy, 2026, 33, 2064-2071.	2.1	0
42	Antiplatelet Therapy for Peripheral Arterial Disease. , 2025, .		0
43	Revascularization for Claudication in the Setting of Multi-Level And/Or Bilateral Disease: How Many Levels to Treat and How. , 2025, .		0
44	Dual Pathway Inhibition: Redefining the Secondary Prevention COMPASS in Chronic Coronary Artery Disease. International Journal of Angiology, 2025, .	1.1	0
45	Critical Limb Ischaemia: Overview and Medical Treatment. , 2026, .		0
46	Antithrombotic Strategies After Lower Extremity Revascularization in Chronic Limb-Threatening Ischemia: A Systematic Review and Network Meta-Analysis. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2026, 4, 100381.	0.9	0
47	Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions, 2026, 19, e015229.	6.2	1
48	Impact of Dual-Pathway Inhibitor Therapy on Outcomes After Femoropopliteal In-Stent Occlusion. Cardiovascular Intervention and Therapeutics, 2026, 41, 660-669.	5.1	0
49	Peripheral Artery Disease Treatment: Scoping Review With ❄SAIMSARA. , 2026, .		0
50	Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation, 2026, 154, 966-975.	24.6	2